Pushback against rising drug prices has caused the iShares Nasdaq Biotechnology ETF to lose 16% of its value this year. Yet while headwinds remain that could slow top-line growth across the industry, selling top-tier biotech stocks like Gilead Sciences, Celgene Corp., and Regeneron Pharmaceuticals might not be the right decision. All three of these companies have lost significant ground this year, but each has catalysts brewing that could reinvigorate share prices.
What’s up with big biotech?
Over the past few years, the biotech industry has benefited from significant double-digit price increases, but revelations last year of triple-digit increases on medicines that have been available for decades have led to significant scrutiny.
